TIDMEVG
Evgen Pharma PLC
16 March 2023
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Further evidence of radiosensitisation by SFX-01 in
Rhabdomyosarcoma cells
Presentation of in vitro results at ESMO Sarcoma and Rare
Cancers Congress
Alderley Park, UK - 16 March 2023 : Evgen Pharma plc (AIM: EVG),
a clinical stage drug development company developing
sulforaphane-based medicines , announces that findings from its
partnership with Prof. Francesco Marampon, Department of
Radiotherapy, Sapienza University of Rome, in collaboration with Dr
Simona Camero of Prof. Francesca Megiorni's research group
(Department of Experimental Medicine, Sapienza University of Rome),
will be presented in a poster at the ESMO Sarcoma and Rare Cancers
Congress (March 20-22), in Lugano Switzerland.
The scientific work evaluates, for the first time, the
anti-tumour activity of SFX-01 in two preclinical cellular models
of rhabdomyosarcoma (RMS) tumours, the most frequent soft tissue
sarcoma in childhood. This disease is mostly diagnosed in children
under 10 years old.
The in vitro data showed that SFX-01 reduced tumour cell growth
by inducing G2 cell cycle arrest and triggering early-apoptosis
(cell death). In addition, SFX-01 was shown to be effective both as
a single agent and in combination with radiotherapy where it was
found to be synergistic; it created a more positive outcome than
would be expected by simply adding the two agents together.
The results also showed that SFX-01 was able to reduce tumour
cell growth in clinically relevant radioresistant RMS cells,
drastically inhibiting the formation of cancer stem cell-derived
tumourspheres (rabdospheres).
Further detail of Dr Camero's work will be available via the
published abstract and poster at the congress. The collaboration
with La Sapienza is ongoing and management looks forward to sharing
further updates in due course.
Dr Huw Jones, Evgen CEO, commented:
"The collaboration with Prof. Marampon's group is giving us
further insight into the mechanisms by which SFX-01 exerts its
antitumour effects and its potential for use alongside
radiotherapy. We are particularly interested to see the effects on
radioresistant cells since r esistance to radiotherapy is a
significant challenge for treatment in metastatic disease. If these
findings translate to the clinic, SFX-01 could be highly impactful
for patients with this hard to treat disease."
Prof. Francesco Marampon, of Università Sapienza di Roma, Lead
Investigator, added:
"Based on previous promising data with SFX-01, we will be
looking to understand the effects of SFX-01 as a potential
radiosensitiser for cancer patients. The ultimate aim is to improve
the impact of radiotherapy and facilitate recovery."
Rhabdomyosarcoma (RMS) is a rare type of cancer that forms in
soft tissue, these sarcomas can develop in muscle, fat, blood
vessels, or in any of the other tissues that support, surround and
protect the organs of the body. RMS can occur at any age, but it
most often affects children. The outlook (prognosis) and treatment
decisions depend on the type of rhabdomyosarcoma, where it starts,
tumour size and whether the cancer has spread (metastasized).
Treatment is usually with a combination of surgery, chemotherapy
and radiation therapy. The long-term outcomes in patients with
metastatic rhabdomyosarcoma remain poor.
SFX-01 is a patented composition of synthetic sulforaphane and
alpha-cyclodextrin. The Company has already completed three trials
in patients, including a positive open label trial in metastatic
breast cancer using the prototype capsule formulation.
Evgen's core technology is Sulforadex(R), a method for
synthesising and stabilising sulforaphane and novel proprietary
analogues based on sulforaphane. Sulforaphanes have shown potential
benefits in neurodevelopmental disorders, oncology and inflammatory
conditions. SFX-01, Evgen's lead asset, is the only stabilised
sulforaphane suitable for clinical research and eventual approval
as a medicine.
-Ends-
Enquiries:
Evgen Pharma PLC
Dr Huw Jones, CEO
Richard Moulson, CFO +44 1625 466591
FinnCap (Nominated Advisor and
Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane/ Nigel Birks (ECM) +44 20 7220 0500
----------------------
Instinctif Partners +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris Evgen@Instinctif.com
/ Adam Loudon
----------------------
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer. In September 2021 the FDA granted Orphan Drug status to
SFX-01 in malignant glioma.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and AsiaPac as part of
the continuing strategy to build safety and efficacy data sets
around the compound. With respect to non-core areas, Evgen signed
an out-licensing deal with JuvLife, the dietary products and
functional foods division of Juvenescence Ltd, for the development
of a naturally-sourced sulforaphane nutritional health supplement,
stabilised using Evgen's Sulforadex(R) technology. Evgen also has a
licensing deal with STALICLA SA in neurodevelopmental disorders and
schizophrenia.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFEDVEIELIV
(END) Dow Jones Newswires
March 16, 2023 03:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024